AA
CRSP icon

Addison Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Addison Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$273 Hold
5
– – ﹤0.01% 672
2026
Q1 		$238 Hold
5
– – ﹤0.01% 956
2025
Q4 		$263 Hold
5
– – ﹤0.01% 877
2025
Q3 		$325 Hold
5
– – ﹤0.01% 862
2025
Q2 		$244 Hold
5
– – ﹤0.01% 857
2025
Q1 		$171 Hold
5
– – ﹤0.01% 820
2024
Q4 		$197 Hold
5
– – ﹤0.01% 822
2024
Q3 		$235 Hold
5
– – ﹤0.01% 816
2024
Q2 		$271 Hold
5
– – ﹤0.01% 754
2024
Q1 		$341 Hold
5
– – ﹤0.01% 676
2023
Q4 		$313 Hold
5
– – ﹤0.01% 684
2023
Q3 		$227 Buy
+5
New +$258 ﹤0.01% 657

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Addison Advisors's CRSP Position: Q2 2026 in Review

Addison Advisors held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 5 shares worth $273. The position accounts for ﹤0.01% of the portfolio, ranked #672.

Addison Advisors first reported a position in CRSP in Q3 2023 and has held it in 12 quarters since. The position peaked at $341 in Q1 2024. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Addison Advisors held 5 shares of CRISPR Therapeutics worth $273 as of Q2 2026.
  • Addison Advisors left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Addison Advisors's portfolio in Q2 2026, its #672 holding.
  • Addison Advisors first reported a position in CRISPR Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Addison Advisors's CRISPR Therapeutics position peaked at $341 in Q1 2024.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Addison Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.